Hillevax, Inc. (HLVX)

$14.03

+0.19

(+1.37%)

Market is closed - opens 8 PM, 29 Nov 2023

Insights on Hillevax, Inc.

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 76.9% return, outperforming this stock by 104.2%

Performance

  • $13.71
    $14.10
    $14.03
    downward going graph

    2.28%

    Downside

    Day's Volatility :2.76%

    Upside

    0.5%

    downward going graph
  • $9.94
    $22.21
    $14.03
    downward going graph

    29.15%

    Downside

    52 Weeks Volatility :55.25%

    Upside

    36.83%

    downward going graph

Returns

PeriodHillevax, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
9.58%
-2.6%
0.0%
6 Months
-16.27%
2.2%
0.0%
1 Year
-27.27%
-4.3%
-3.4%
3 Years
-27.5%
19.1%
-4.7%

Highlights

Market Capitalization
667.9M
Book Value
$6.56
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.29
Wall Street Target Price
28.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-21.07%
Return On Equity TTM
-36.8%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-115.7M
Diluted Eps TTM
-2.29
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.08
EPS Estimate Next Year
-3.21
EPS Estimate Current Quarter
-0.84
EPS Estimate Next Quarter
-1.06

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Hillevax, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 101.35%

Current $14.03
Target $28.25

Technicals Summary

Sell

Neutral

Buy

Hillevax, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Hillevax, Inc.
Hillevax, Inc.
29.35%
-16.27%
-27.27%
-27.5%
-27.5%
Moderna, Inc.
Moderna, Inc.
4.93%
-38.23%
-55.68%
-49.12%
317.85%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.62%
9.54%
7.63%
54.66%
119.47%
Novo Nordisk A/s
Novo Nordisk A/s
7.75%
29.99%
71.36%
209.46%
351.9%
Seagen, Inc.
Seagen, Inc.
0.13%
10.52%
76.89%
25.9%
249.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.03%
7.65%
11.07%
53.76%
96.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Hillevax, Inc.
Hillevax, Inc.
NA
NA
NA
-3.08
-0.37
-0.21
0.0
6.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.11
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.51
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.76
41.76
2.03
2.65
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.68
26.68
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Hillevax, Inc.
Hillevax, Inc.
Buy
$667.9M
-27.5%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$29.8B
317.85%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
119.47%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$458.4B
351.9%
41.76
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
249.5%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.4B
96.32%
26.68
35.94%

Institutional Holdings

  • Deerfield Management Co

    6.88%
  • The Carlyle Group Inc

    3.80%
  • T. Rowe Price Investment Management,Inc.

    2.94%
  • Franklin Resources Inc

    2.65%
  • BlackRock Inc

    2.62%
  • BRAIDWELL LP

    2.58%

Company Information

hillevax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. our initial program, hil-214, is a virus-like particle (vlp) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Organization
Hillevax, Inc.
Employees
62
CEO
Dr. Robert M. Hershberg M.D., Ph.D.
Industry
Services

FAQs